Skip to Content

Posts tagged with "Academia (vs. Industry)"

  • Academia (vs. Industry)

    Want Your Compounds Tested Against Pathogens For Free?

    I’d like to help publicize what seems like a very worthwhile effort, funded by the University of Queensland and the Wellcome Trust: the Community for Open Antimicrobial Drug Discovery (CO-ADD). Here’s a writeup on them in Nature – what they’re doing is taking compounds from all sources and screening them against panels of i… Read More
  • Academia (vs. Industry)

    A Professor’s View On Drug Company Collaborations

    My post the other day on Phil Baran’s public-private funding ideas brought in a lot of comment. As usual, I encourage a look a the comments section if you’re interested in the topic, or any topic that comes up around here – a lot of people who know whereof they speak show up. But I… Read More
  • Academia (vs. Industry)

    Don’t Wait For the Public Sector

    If you haven’t seen this speech by Phil Baran, given at his induction into the American Academy of Arts and Sciences, it’s worth a look. His main theme is what organic chemists can learn from the business model of SpaceX, and he starts out by talking about how grant money for synthetic organic chemistry has… Read More
  • Academia (vs. Industry)

    Stand By Your Data With Some Cash

    Reproducibility in the scientific literature has been a big issue for some time now, and it’s not going away any time soon. There are arguments and counterarguments about how much of the literature is not reproducible, how reproducible the attempts to reproduce it are, what the standards should be for such efforts, and how much… Read More
  • Academia (vs. Industry)

    Trouble At UC-Berkeley

    There have been a lot of recent news items about trouble in the chemistry department at UC-Berkeley. (This article at the campus’s Daily Californian a week ago seems to be have kicked off the story, and good for them if it did). The situation is not good, but it doesn’t seem to be as catastrophic… Read More
  • Academia (vs. Industry)

    Drugs Purely From Academia

    I see that there’s an investment fund in Europe saying that “Every year, around 30 to 40 percent of the drugs approved by the FDA (U.S. Food and Drug Administration) were actually discovered in European academic labs“. Meanwhile the European Medicines Agency says that “Academia and other public-private partnerships helped to… Read More
  • Academia (vs. Industry)

    What Does One Do With These?

    A reader sends pointed me to this paper, whose title they found interesting: “Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death”. An unusual mechanism, for sure – so what is this compound, exactly? You have to go into the Supporting Info… Read More
  • Academia (vs. Industry)

    Clinical Trials: NIH and the Drug Industry

    JAMA has an article out on who funds and conducts clinical trials. It shouldn’t surprise anyone  (although it does seem to be news to some headline writers) that industry funds the great majority of them. What does stand out is that the proportion funded by industry is increasing, although that shouldn’t necessarily be news, either. … Read More
  • Academia (vs. Industry)

    Technology and Funding: Myths and Alternate Worlds

    Science writer Matt Ridley had an interesting (but somewhat odd) column over the weekend in the Wall Street Journal. Titled “The Myth of Basic Science”, it maintains that “technological innovation has a momentum of its own”, and that basic research doesn’t really drive it. I think that my brain must be about ninety deg… Read More
  • Academia (vs. Industry)

    Magic Open Source Savings Await

    I’ve never known quite what to make of the “open source pharma” idea. I know that there are a lot of people working on things in this area, and that there’s a lot of interest. But as someone who does drug discovery for a living, I can’t quite see how it can work. And I’m… Read More
123...